miR-181c associates with tumor relapse of high grade osteosarcoma

Mori Federica, Sacconi Andrea, Canu Valeria, Ganci Federica, Novello Mariangela, Anelli Vincenzo, Covello Renato, Ferraresi Virginia, Muti Paola, Biagini Roberto, Blandino Giovanni, Strano Sabrina

Research output: Contribution to journalArticle

Abstract

High-grade osteosarcoma (OS) is characterized by low incidence, high aggressiveness and moderate 5-years survival rate after aggressive polychemotherapy and surgery. Here we used miRNA profiling as a tool to possibly predict and monitor OS's development and therapeutic outcome. First, we evaluated the altered expression of selected miRNAs from a case of Giant Cell Tumor (GCT) apparently evolved into an OS. We found that most of modulated miRs were associated with pathways of bone resorption and osteogenesis. miRNA expression also revealed that GCT and OS were distinct tumors. Second, we validated the observed miRNA profile in two independent casuistries of ten GCT (not evolved into malignant tumors) and sixteen OS patients. Interestingly, we found that miR-181c and other three miRNAs identified in the first step of the study were also consistently de-regulated in all OS patients. Ectopic expression of miR-181c reduced cell viability and enhanced chemotherapeutic-induced cell death of U2OS and SAOS2 cells. These findings indicate that: i) miRNAs aberrantly modulated in GCT could be predictive of its development into OS and ii) miRNAs expression could be useful to monitor the OS therapeutic outcome.

Original languageEnglish
Pages (from-to)13947-13961
Number of pages15
JournalOncotarget
Volume6
Issue number16
Publication statusPublished - 2015

Fingerprint

Osteosarcoma
MicroRNAs
Giant Cell Tumors
Recurrence
Neoplasms
Casuistry
Bone Resorption
Combination Drug Therapy
Osteogenesis
Cell Survival
Cell Death
Survival Rate
Incidence
Therapeutics

Keywords

  • Giant cell tumor
  • miRNA profiling
  • Osteosarcoma
  • Relapse

ASJC Scopus subject areas

  • Oncology

Cite this

Federica, M., Andrea, S., Valeria, C., Federica, G., Mariangela, N., Vincenzo, A., ... Sabrina, S. (2015). miR-181c associates with tumor relapse of high grade osteosarcoma. Oncotarget, 6(16), 13947-13961.

miR-181c associates with tumor relapse of high grade osteosarcoma. / Federica, Mori; Andrea, Sacconi; Valeria, Canu; Federica, Ganci; Mariangela, Novello; Vincenzo, Anelli; Renato, Covello; Virginia, Ferraresi; Paola, Muti; Roberto, Biagini; Giovanni, Blandino; Sabrina, Strano.

In: Oncotarget, Vol. 6, No. 16, 2015, p. 13947-13961.

Research output: Contribution to journalArticle

Federica, M, Andrea, S, Valeria, C, Federica, G, Mariangela, N, Vincenzo, A, Renato, C, Virginia, F, Paola, M, Roberto, B, Giovanni, B & Sabrina, S 2015, 'miR-181c associates with tumor relapse of high grade osteosarcoma', Oncotarget, vol. 6, no. 16, pp. 13947-13961.
Federica M, Andrea S, Valeria C, Federica G, Mariangela N, Vincenzo A et al. miR-181c associates with tumor relapse of high grade osteosarcoma. Oncotarget. 2015;6(16):13947-13961.
Federica, Mori ; Andrea, Sacconi ; Valeria, Canu ; Federica, Ganci ; Mariangela, Novello ; Vincenzo, Anelli ; Renato, Covello ; Virginia, Ferraresi ; Paola, Muti ; Roberto, Biagini ; Giovanni, Blandino ; Sabrina, Strano. / miR-181c associates with tumor relapse of high grade osteosarcoma. In: Oncotarget. 2015 ; Vol. 6, No. 16. pp. 13947-13961.
@article{6c449b7c7c724924bcb2c908bdca0639,
title = "miR-181c associates with tumor relapse of high grade osteosarcoma",
abstract = "High-grade osteosarcoma (OS) is characterized by low incidence, high aggressiveness and moderate 5-years survival rate after aggressive polychemotherapy and surgery. Here we used miRNA profiling as a tool to possibly predict and monitor OS's development and therapeutic outcome. First, we evaluated the altered expression of selected miRNAs from a case of Giant Cell Tumor (GCT) apparently evolved into an OS. We found that most of modulated miRs were associated with pathways of bone resorption and osteogenesis. miRNA expression also revealed that GCT and OS were distinct tumors. Second, we validated the observed miRNA profile in two independent casuistries of ten GCT (not evolved into malignant tumors) and sixteen OS patients. Interestingly, we found that miR-181c and other three miRNAs identified in the first step of the study were also consistently de-regulated in all OS patients. Ectopic expression of miR-181c reduced cell viability and enhanced chemotherapeutic-induced cell death of U2OS and SAOS2 cells. These findings indicate that: i) miRNAs aberrantly modulated in GCT could be predictive of its development into OS and ii) miRNAs expression could be useful to monitor the OS therapeutic outcome.",
keywords = "Giant cell tumor, miRNA profiling, Osteosarcoma, Relapse",
author = "Mori Federica and Sacconi Andrea and Canu Valeria and Ganci Federica and Novello Mariangela and Anelli Vincenzo and Covello Renato and Ferraresi Virginia and Muti Paola and Biagini Roberto and Blandino Giovanni and Strano Sabrina",
year = "2015",
language = "English",
volume = "6",
pages = "13947--13961",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "16",

}

TY - JOUR

T1 - miR-181c associates with tumor relapse of high grade osteosarcoma

AU - Federica, Mori

AU - Andrea, Sacconi

AU - Valeria, Canu

AU - Federica, Ganci

AU - Mariangela, Novello

AU - Vincenzo, Anelli

AU - Renato, Covello

AU - Virginia, Ferraresi

AU - Paola, Muti

AU - Roberto, Biagini

AU - Giovanni, Blandino

AU - Sabrina, Strano

PY - 2015

Y1 - 2015

N2 - High-grade osteosarcoma (OS) is characterized by low incidence, high aggressiveness and moderate 5-years survival rate after aggressive polychemotherapy and surgery. Here we used miRNA profiling as a tool to possibly predict and monitor OS's development and therapeutic outcome. First, we evaluated the altered expression of selected miRNAs from a case of Giant Cell Tumor (GCT) apparently evolved into an OS. We found that most of modulated miRs were associated with pathways of bone resorption and osteogenesis. miRNA expression also revealed that GCT and OS were distinct tumors. Second, we validated the observed miRNA profile in two independent casuistries of ten GCT (not evolved into malignant tumors) and sixteen OS patients. Interestingly, we found that miR-181c and other three miRNAs identified in the first step of the study were also consistently de-regulated in all OS patients. Ectopic expression of miR-181c reduced cell viability and enhanced chemotherapeutic-induced cell death of U2OS and SAOS2 cells. These findings indicate that: i) miRNAs aberrantly modulated in GCT could be predictive of its development into OS and ii) miRNAs expression could be useful to monitor the OS therapeutic outcome.

AB - High-grade osteosarcoma (OS) is characterized by low incidence, high aggressiveness and moderate 5-years survival rate after aggressive polychemotherapy and surgery. Here we used miRNA profiling as a tool to possibly predict and monitor OS's development and therapeutic outcome. First, we evaluated the altered expression of selected miRNAs from a case of Giant Cell Tumor (GCT) apparently evolved into an OS. We found that most of modulated miRs were associated with pathways of bone resorption and osteogenesis. miRNA expression also revealed that GCT and OS were distinct tumors. Second, we validated the observed miRNA profile in two independent casuistries of ten GCT (not evolved into malignant tumors) and sixteen OS patients. Interestingly, we found that miR-181c and other three miRNAs identified in the first step of the study were also consistently de-regulated in all OS patients. Ectopic expression of miR-181c reduced cell viability and enhanced chemotherapeutic-induced cell death of U2OS and SAOS2 cells. These findings indicate that: i) miRNAs aberrantly modulated in GCT could be predictive of its development into OS and ii) miRNAs expression could be useful to monitor the OS therapeutic outcome.

KW - Giant cell tumor

KW - miRNA profiling

KW - Osteosarcoma

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84931035414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931035414&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84931035414

VL - 6

SP - 13947

EP - 13961

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -